BNIP3L

Across TCGA pan-cancer cohorts, BNIP3L Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BNIP3L data layer compared with 20 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher BNIP3L Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated BNIP3L expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, BLCA, and KICH are the cancer types where BNIP3L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.945	0.428	.005	32	view →
BLCA	OS	Median	All	0.082	0.688	<.001	30	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
SKCM	DFS	Median	All	0.046	0.757	<.001	13	view →
LUAD	OS	Median	II,III,IV	0.540	0.709	.026	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BNIP3L–UCEC (DFS)

Open the UCEC breakdown →